Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 57.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,065 shares of the biopharmaceutical company’s stock after selling 1,431 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Creative Planning grew its holdings in shares of Regeneron Pharmaceuticals by 11.5% during the 2nd quarter. Creative Planning now owns 9,615 shares of the biopharmaceutical company’s stock worth $10,106,000 after purchasing an additional 991 shares during the period. NewEdge Advisors LLC lifted its position in Regeneron Pharmaceuticals by 6.3% in the second quarter. NewEdge Advisors LLC now owns 4,368 shares of the biopharmaceutical company’s stock valued at $4,591,000 after buying an additional 260 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Regeneron Pharmaceuticals by 16.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,821 shares of the biopharmaceutical company’s stock valued at $4,016,000 after buying an additional 536 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 8.0% during the second quarter. B. Riley Wealth Advisors Inc. now owns 1,086 shares of the biopharmaceutical company’s stock valued at $1,142,000 after acquiring an additional 80 shares during the last quarter. Finally, New Century Financial Group LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $313,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Evercore ISI lowered their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $687.27 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The stock has a market cap of $75.52 billion, a PE ratio of 17.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The firm has a fifty day moving average price of $724.48 and a 200 day moving average price of $930.31.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.